288 related articles for article (PubMed ID: 36313502)
1. Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment.
Jayaraman S; Jayaraman A
Front Neurol; 2022; 13():980758. PubMed ID: 36313502
[TBL] [Abstract][Full Text] [Related]
2. The epigenetic drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord.
Jayaraman A; Soni A; Prabhakar BS; Holterman M; Jayaraman S
Neurobiol Dis; 2017 Dec; 108():1-12. PubMed ID: 28736194
[TBL] [Abstract][Full Text] [Related]
3. Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains.
Tsunoda I; Kuang LQ; Theil DJ; Fujinami RS
Brain Pathol; 2000 Jul; 10(3):402-18. PubMed ID: 10885659
[TBL] [Abstract][Full Text] [Related]
4. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.
Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA
Front Immunol; 2020; 11():668. PubMed ID: 32431694
[TBL] [Abstract][Full Text] [Related]
5. Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis.
Tremolanti C; Cavallini C; Meyer L; Klein C; Da Pozzo E; Costa B; Germelli L; Taliani S; Patte-Mensah C; Mensah-Nyagan AG
Mol Neurobiol; 2022 Mar; 59(3):1744-1765. PubMed ID: 35018577
[TBL] [Abstract][Full Text] [Related]
6. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
7. Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS).
Glatigny S; Bettelli E
Cold Spring Harb Perspect Med; 2018 Nov; 8(11):. PubMed ID: 29311122
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and Management of Progressive Multiple Sclerosis.
Macaron G; Ontaneda D
Biomedicines; 2019 Jul; 7(3):. PubMed ID: 31362384
[TBL] [Abstract][Full Text] [Related]
9. Cytokine production profiles in chronic relapsing-remitting experimental autoimmune encephalomyelitis: IFN-γ and TNF-α are important participants in the first attack but not in the relapse.
Hidaka Y; Inaba Y; Matsuda K; Itoh M; Kaneyama T; Nakazawa Y; Koh CS; Ichikawa M
J Neurol Sci; 2014 May; 340(1-2):117-22. PubMed ID: 24655735
[TBL] [Abstract][Full Text] [Related]
10. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis.
Johns TG; Kerlero de Rosbo N; Menon KK; Abo S; Gonzales MF; Bernard CC
J Immunol; 1995 May; 154(10):5536-41. PubMed ID: 7537310
[TBL] [Abstract][Full Text] [Related]
11. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M
Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096
[TBL] [Abstract][Full Text] [Related]
12. Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Al-Izki S; Pryce G; Hankey DJ; Lidster K; von Kutzleben SM; Browne L; Clutterbuck L; Posada C; Edith Chan AW; Amor S; Perkins V; Gerritsen WH; Ummenthum K; Peferoen-Baert R; van der Valk P; Montoya A; Joel SP; Garthwaite J; Giovannoni G; Selwood DL; Baker D
Brain; 2014 Jan; 137(Pt 1):92-108. PubMed ID: 24287115
[TBL] [Abstract][Full Text] [Related]
13. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
Petratos S; Ozturk E; Azari MF; Kenny R; Lee JY; Magee KA; Harvey AR; McDonald C; Taghian K; Moussa L; Mun Aui P; Siatskas C; Litwak S; Fehlings MG; Strittmatter SM; Bernard CC
Brain; 2012 Jun; 135(Pt 6):1794-818. PubMed ID: 22544872
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019.
Martinez B; Peplow PV
Neural Regen Res; 2020 Jul; 15(7):1220-1234. PubMed ID: 31960801
[TBL] [Abstract][Full Text] [Related]
15. Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective.
Skundric DS
Curr Neurovasc Res; 2005 Oct; 2(4):349-62. PubMed ID: 16181126
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.
De Angelis F; Plantone D; Chataway J
CNS Drugs; 2018 Jun; 32(6):499-526. PubMed ID: 29968175
[TBL] [Abstract][Full Text] [Related]
17. [Astrocytes in the pathogenesis of multiple sclerosis].
Takarada-Iemata M; Hori O
Nihon Yakurigaku Zasshi; 2021; 156(4):230-234. PubMed ID: 34193702
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of progressive autoimmune encephalomyelitis by epigenetic regulation involves selective repression of mature neutrophils during the preclinical phase.
Jayaraman A; Sharma M; Prabhakar B; Holterman M; Jayaraman S
Exp Neurol; 2018 Jun; 304():14-20. PubMed ID: 29453977
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis.
Martinez B; Peplow PV
Neural Regen Res; 2020 Oct; 15(10):1831-1837. PubMed ID: 32246624
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil perversion in demyelinating autoimmune diseases: Mechanisms to medicine.
Casserly CS; Nantes JC; Whittaker Hawkins RF; Vallières L
Autoimmun Rev; 2017 Mar; 16(3):294-307. PubMed ID: 28161558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
